Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) – For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of MI and stroke. FDA label
Also known as Plavix
Clopidogrel · 3 trials · 5 indications
The outcome measurement was on-treatment PRI determined through flow cytometric assessment of phosphorylation status of VASP.
| Arm | Type | Description |
|---|---|---|
| Clopidogrel - for CYP2C19*2 carriers | ACTIVE_COMPARATOR | Clopidogrel for CYP2C19\*2 gene carriers |
| Clopidogrel - for CYP2C19*2 non-carriers | ACTIVE_COMPARATOR | Clopidogrel for CYP2C19\*2 gene NON-carriers |
| Clopidogrel + Aspirin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Aspirin | DRUG | - |
| Clopidogrel | DRUG | - |
Inclusion Criteria: * Patients 18 years of age or older * Undergoing on-pump, elective coronary artery bypass grafting with at least 2 free grafts * Patient able to give informed consent Exclusion Criteria: * planned date of surgery is \<5 days from planned recruitment date * patient has clear in...
Top 11 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Inclisiran, YMI024 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Viatris, Inc. | VTRS | 2 | PHASE3 | Selatogrel |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| Humacyte, Inc. | HUMA | 1 | PHASE2 | CTEV |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 2 | - | alirocumab |
| Bayer | BAYRY | 1 | PHASE1 | Nurandociguat |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7763505 |
Clopidogrel is a small molecule drug developed by Bristol-Myers Squibb Company (ticker: BMY). It is being studied in cardiovascular disease, coronary artery disease, and myocardial infarction. The drug is in Phase 1 development. It is an antagonist of P2RY12.
Clopidogrel is used for cardiovascular disease, coronary artery disease, and myocardial infarction. It is being developed by Bristol-Myers Squibb Company (BMY). The drug is in Phase 1 of clinical development.
Clopidogrel targets P2RY12, a receptor. It acts as an antagonist. This mechanism is relevant to its development for cardiovascular disease, coronary artery disease, and myocardial infarction.
Clopidogrel is made by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is developing the drug for cardiovascular disease, coronary artery disease, and myocardial infarction.
Clopidogrel is in Phase 1 of clinical development. It is investigational and has not been approved by the FDA. The drug is being developed by Bristol-Myers Squibb Company (BMY).
Clopidogrel has been studied in clinical trials including NCT01235351, a Phase 2 trial in myocardial infarction and percutaneous coronary intervention; NCT00935506, a Phase 1 trial in cardiovascular disease; and NCT00330772, a Phase 3 trial in coronary artery disease and coronary artery bypass grafting. All are completed.